Biotechnology innovations frequently rely on the identification, modification, or application of nucleotide and amino acid sequences. Whether an invention relates to recombinant DNA technology, vaccines, monoclonal antibodies, gene-editing systems, molecular diagnostics, synthetic biology, agricultural biotechnology, or cell and gene therapies, biological sequence information often constitutes a fundamental aspect of the patent disclosure.
To ensure uniformity in the presentation and examination of biological sequence data, the Brazilian National Institute of Industrial Property (INPI) has adopted internationally recognized sequence listing standards established by the World Intellectual Property Organization (WIPO). Patent applicants seeking protection for biotechnology inventions in Brazil must therefore prepare and submit sequence listings that fully comply with the applicable technical requirements.
A properly prepared sequence listing is far more than a procedural formality. It forms an integral part of the patent application and directly affects examination efficiency, legal certainty, and international patent prosecution. Failure to submit a compliant sequence listing may result in formal objections, examination delays, requests for correction, or additional administrative costs.
This guide provides a detailed overview of Brazil’s sequence listing requirements, the implementation of WIPO Standard ST.26, filing procedures before the INPI, common compliance challenges, and best practices for preparing biotechnology patent applications.
Understanding Sequence Listings
A sequence listing is a standardized document that contains nucleotide and amino acid sequences disclosed in a patent application. Instead of including lengthy DNA, RNA, or protein sequences throughout the written specification, the sequences are organized in a structured electronic format that allows patent offices to efficiently process, publish, index, search, and examine biological information.
Sequence listings serve several important purposes:
- Standardize the presentation of biological sequence information.
- Facilitate prior art searches conducted by patent examiners.
- Improve interoperability among international patent offices.
- Enable electronic database indexing and comparison of disclosed sequences.
- Reduce ambiguity in the disclosure of biological inventions.
- Improve consistency between national and international patent filings.
The sequence listing forms part of the technical disclosure of the invention and should accurately reflect every nucleotide or amino acid sequence referenced in the specification.
Brazil’s Adoption of WIPO Standard ST.26
Brazil has modernized its biotechnology patent filing system by adopting WIPO Standard ST.26, replacing the older ST.25 sequence listing standard for applicable patent applications.
The transition reflects the worldwide modernization of biological sequence reporting and aligns Brazil with numerous patent offices, including those of the United States, Europe, Japan, China, South Korea, Australia, Canada, and many other jurisdictions.
For patent applications filed on or after 1 July 2022, biological sequence listings must generally comply with ST.26 and be submitted in XML (Extensible Markup Language) format.
Unlike ST.25, which relied primarily on plain text formatting, ST.26 introduces a structured XML framework that allows sequence information to be processed more accurately using automated software systems.
The Brazilian INPI recommends preparing sequence listings using the official WIPO Sequence software, a free application developed by WIPO specifically for creating, editing, validating, and exporting ST.26-compliant sequence listings.
Advantages of ST.26
The implementation of ST.26 offers several advantages over the previous standard, including:
- Greater international harmonization.
- Improved machine readability.
- Enhanced biological data consistency.
- Better integration with patent databases.
- Reduced interpretation errors.
- Simplified electronic filing.
- More efficient patent examination.
- Easier management of international patent portfolios.
For applicants pursuing patent protection in multiple countries, compliance with ST.26 significantly reduces the need for jurisdiction-specific sequence listing revisions.
When Is a Sequence Listing Required?
A sequence listing is generally required whenever the patent application discloses nucleotide or amino acid sequences that are essential for understanding, reproducing, or practicing the invention.
Typical biotechnology inventions requiring sequence listings include:
- DNA molecules
- RNA molecules
- Messenger RNA (mRNA)
- Complementary DNA (cDNA)
- Synthetic nucleotide sequences
- Gene fragments
- Protein sequences
- Peptides
- Antibodies
- Recombinant proteins
- Gene editing constructs
- CRISPR-associated sequences
- Expression vectors
- Viral genomes
- Plasmids
- Fusion proteins
- Engineered enzymes
- Aptamers
- Small interfering RNA (siRNA)
- MicroRNA (miRNA)
- Guide RNA (gRNA)
Applications involving biotechnology, pharmaceuticals, diagnostics, veterinary medicine, industrial biotechnology, food technology, environmental biotechnology, agricultural biotechnology, and synthetic biology frequently require sequence listings.
Applicants should carefully analyze the patent specification to determine whether biological sequences meet the reporting thresholds established under ST.26.
Patent Applications Commonly Requiring Sequence Listings
Sequence listings commonly appear in patent applications relating to:
Pharmaceutical Biotechnology
- Therapeutic proteins
- Recombinant hormones
- Cytokines
- Growth factors
- Monoclonal antibodies
- Biosimilars
- Personalized medicine
Molecular Diagnostics
- PCR primers
- Diagnostic probes
- Biomarker sequences
- Companion diagnostics
- Cancer diagnostics
Gene Therapy
- Viral vectors
- Therapeutic genes
- Genome editing systems
- Gene replacement technologies
Vaccine Technologies
- DNA vaccines
- RNA vaccines
- Recombinant vaccines
- Protein subunit vaccines
- Viral antigen sequences
Agricultural Biotechnology
- Genetically modified crops
- Pest-resistant plants
- Herbicide-resistant plants
- Plant breeding innovations
- Seed technologies
Industrial Biotechnology
- Engineered microorganisms
- Fermentation technologies
- Enzyme engineering
- Biofuel production
- Biocatalysts
Documents Required for Filing Before the INPI
A biotechnology patent application submitted to the INPI generally consists of the following documents:
- Patent request form
- Detailed specification describing the invention
- One or more patent claims
- Abstract
- Patent drawings (when applicable)
- ST.26 sequence listing in XML format (when required)
- Power of attorney (where applicable)
- Assignment documents (if ownership has been transferred)
- Priority documents for convention applications
- Portuguese translation where required
- Payment of official filing fees
Each component should be internally consistent, particularly with respect to sequence identifiers and references.
Preparing an ST.26 Sequence Listing
Preparing a compliant sequence listing requires careful coordination between inventors, patent attorneys, and biotechnology specialists.
The sequence listing must accurately describe every disclosed nucleotide and amino acid sequence while complying with the formatting requirements established by WIPO Standard ST.26.
Information typically included includes:
- Sequence identification number
- Molecule type
- Sequence length
- Organism source
- Genetic code information
- Sequence features
- Modifications
- Artificial sequence designation where applicable
- Circular or linear molecule designation
- Sequence residues
Every sequence referenced in the specification should correspond exactly with the sequence listing.
Even minor inconsistencies between the written specification and the XML file may generate examination objections.
Using WIPO Sequence Software
WIPO provides dedicated software for preparing ST.26 sequence listings.
The software enables applicants to:
- Create new sequence listings
- Import existing biological sequence data
- Validate XML structure
- Detect formatting errors
- Verify mandatory fields
- Export compliant XML files
- Update existing sequence listings
- Ensure compatibility with international patent offices
Applicants are strongly encouraged to perform validation before filing to minimize formal deficiencies.
Common Filing Errors
Despite standardized software, sequence listing preparation remains one of the most technically demanding aspects of biotechnology patent drafting.
Common mistakes include:
- Missing sequences
- Duplicate sequence identifiers
- Incorrect sequence numbering
- Invalid XML formatting
- Missing mandatory descriptors
- Inconsistent sequence references
- Improper molecule classifications
- Incorrect amino acid translations
- Failure to disclose sequence variants
- Incorrect organism names
- Missing modified residue information
- Errors during conversion from ST.25 to ST.26
- Validation failures
- Mismatches between claims and sequence listings
These errors frequently result in office actions requesting corrections before substantive examination proceeds.
ST.25 to ST.26 Transition
Many biotechnology companies continue to maintain patent portfolios containing applications filed under both standards.
Generally:
- Applications filed before 1 July 2022 remain subject to ST.25 transitional rules where applicable.
- Applications filed on or after 1 July 2022 generally require compliance with ST.26.
Applicants entering the Brazilian national phase from an international Patent Cooperation Treaty (PCT) application should ensure that the applicable sequence listing complies with the filing date requirements.
Understanding these transitional provisions is particularly important when managing international patent portfolios.
International Filing Considerations
Brazil’s alignment with ST.26 significantly benefits applicants seeking worldwide patent protection.
International applicants often file through:
- The Patent Cooperation Treaty (PCT)
- Direct national filings
- Paris Convention priority applications
Because most major patent offices now require ST.26-compliant sequence listings, preparing an accurate XML sequence listing during the initial filing stage can reduce duplication of work throughout global prosecution.
Consistency across jurisdictions also minimizes discrepancies that could complicate examination, amendment, or enforcement.
Applicants should ensure that:
- Sequence identifiers remain identical across jurisdictions.
- Biological disclosures are consistent in every application.
- Amendments comply with applicable patent laws.
- Priority documents accurately correspond to sequence listings.
- National phase entries include the correct XML files.
Examination of Sequence Listings by the INPI
During formal examination, the INPI reviews sequence listings to determine whether they satisfy applicable filing requirements.
The Office may verify: